Narayan Andrea J, Hayley Amie C, Rose Sarah, Di Natale Lauren, Downey Luke A
Centre for Mental Health & Brain Sciences, Swinburne University of Technology, Hawthorn, 3122, Australia.
Institute for Breathing and Sleep, Austin Hospital, Melbourne, Australia.
Psychopharmacology (Berl). 2025 Feb;242(2):297-308. doi: 10.1007/s00213-024-06674-x. Epub 2024 Aug 17.
Cannabidiol (CBD) is increasingly used as a sleep aid for insomnia; yet neurocognitive and subjective state effects following daily therapeutic use are unclear.
To measure the effect of daily CBD use on neurocognitive performance and daily subjective mood in a population with primary insomnia.
This study used a randomized, placebo-controlled, parallel design incorporating a single-blind placebo run-in week followed by a two-week double-blind dosing period, during which participants consumed 150 mg CBD (N = 15) or placebo (N = 15) sublingually 60-minutes daily before bed. Attention, executive function, reasoning, information processing, working and episodic memory were assessed using the CogPro system at the beginning of the placebo run-in, after 1-week and 2-weeks of dosing. Subjective states using visual analogue scales and side effects were recorded daily.
Cognitive performance was unaffected by nightly CBD supplementation (all p > 0.05). From baseline to trial conclusion, those receiving CBD reported greater experience of calmness, clear-headedness, coordination and were more likely to report side-effects of dry mouth relative to placebo (all p < 0.05).
Relative to placebo, daytime cognitive functioning following nightly supplementation as a therapeutic aid for primary insomnia was preserved under trial conditions. Results suggested an overall favourable safety profile, with larger controlled trials and thorough analyses of varying insomnia phenotypes necessary to corroborate these findings.
大麻二酚（CBD）越来越多地被用作失眠的助眠药物；然而，每日治疗性使用后的神经认知和主观状态影响尚不清楚。
测量每日使用CBD对原发性失眠人群神经认知表现和日常主观情绪的影响。
本研究采用随机、安慰剂对照、平行设计，包括单盲安慰剂导入期1周，随后是为期两周的双盲给药期，在此期间，参与者在每天睡前60分钟舌下含服150毫克CBD（N = 15）或安慰剂（N = 15）。在安慰剂导入期开始时、给药1周和2周后，使用CogPro系统评估注意力、执行功能、推理、信息处理、工作和情景记忆。每天使用视觉模拟量表记录主观状态和副作用。
每晚补充CBD对认知表现无影响（所有p > 0.05）。从基线到试验结束，与安慰剂相比，接受CBD的人报告有更强烈的平静、头脑清醒、协调的体验，并且更有可能报告口干的副作用（所有p < 0.05）。
相对于安慰剂，在试验条件下，每晚补充作为原发性失眠治疗辅助手段后的白天认知功能得以保留。结果表明总体安全性良好，需要更大规模的对照试验和对不同失眠表型进行全面分析来证实这些发现。
